Last reviewed · How we verify
Carbidopa capsule
At a glance
| Generic name | Carbidopa capsule |
|---|---|
| Sponsor | Impax Laboratories, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dyskinesia
- Constipation
- Fall
- Parkinson's Disease
- Insomnia
- Nausea
- Somnolence
- Arthralgia
- Back Pain
- Headache
- Diarrhoea
- FALL
Key clinical trials
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease (PHASE4)
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- Relative Bioavailability Study of HRG2010 in Healthy Subjects (PHASE1)
- eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (PHASE4)
- Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
- Enhancement of Stroke Rehabilitation With Levodopa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbidopa capsule CI brief — competitive landscape report
- Carbidopa capsule updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI